Dallas, TX -- (SBWIRE) -- 02/12/2015 -- The report "Oral Mucositis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Oral Mucositis. Oral mucositis is a common complication of chemotherapy & it is caused by a virus, fungus or bacteria, immune deficiency and medications. One of the main causes of mucositis is high dose cancer therapy. Oral mucositis affects almost 0.5 million persons each year. Treatment is based on the cause of symptoms. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available @ http://www.rnrmarketresearch.com/oral-mucositis-pipeline-review-h1-2015-market-report.html.

The report also reviews key players involved in the therapeutic development for oral mucositis and special features on late-stage and discontinued projects. Companies discussed in this Oral Mucositis – Pipeline Review, H1 2015 report include ActogeniX NV, Alder Biopharmaceuticals Inc., Cellceutix Corporation, Colby Pharmaceutical Company, Daewoong Pharmaceutical Co., Ltd., GliaMed, Inc., Laila Pharmaceuticals Pvt. Ltd., Onxeo SA, Otsuka Holdings Co., Ltd., ProCertus BioPharm Inc., Soligenix, Inc., Spectrum Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc.

Signs and symptoms of oral mucositis are mouth pain, mouth sores, infection, bleeding, dry mouth and white patches. Drugs profile discussed in this report includes AG-013, AP-001, AP-002, brilacidin, clazakizumab, clonidine hydrochloride ER, cobiprostone, GC-4403, GC-4419, Gene Therapy for Oral Mucositis, GM-1485, JVRSOD, LP-00409, nepidermin, OralX, pralatrexate, rebamipide, Regenasyn and SGX-942. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269528 . (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this "High Oral Mucositis – Pipeline Review, H1 2015" report include: Jan 05, 2015: Soligenix Announces Positive Preliminary Nonclinical Results in Macrophage Activation Syndrome; Dec 08, 2014: Cellceutix Antibiotic Brilacidin Receives QIDP Designation From FDA; Nov 24, 2014: Cellceutix Provides Update On lead drug candidate Brilacidin; Nov 11, 2014: Patient Enrollment in Cellceutix Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis Targeted to Begin in December 2014; Oct 13, 2014: Cellceutix Investigational New Drug Application Becomes Effective, Selects First Site for Phase 2 Clinical Trial of New Treatment for Oral Mucositis; Sep 09, 2014: Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis; Aug 11, 2014: Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis; May 05, 2014: BioAlliance Pharma announces major achievements on Validive: Enrollment completion in the international Phase II trial with Validive in severe oral mucositis, Presentation of preclinical data at the next ASCO annual meeting; Apr 07, 2014: Soligenix Announces $200,000 NIDCR SBIR Grant Award Supporting Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer; Jan 23, 2014: FDA Grants Validive with a Fast Track Designation for the Prevention and Treatment of Oral Mucositis Induced by Anticancer Treatments.

Table of content

List of Tables
Number of Products under Development for Oral Mucositis, H1 2015
Number of Products under Development for Oral Mucositis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Oral Mucositis - Pipeline by ActogeniX NV, H1 2015
Oral Mucositis - Pipeline by Alder Biopharmaceuticals Inc., H1 2015
Oral Mucositis - Pipeline by Cellceutix Corporation, H1 2015
Oral Mucositis - Pipeline by Colby Pharmaceutical Company, H1 2015
Oral Mucositis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015
Oral Mucositis - Pipeline by GliaMed, Inc., H1 2015
Oral Mucositis - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2015
Oral Mucositis - Pipeline by Onxeo SA, H1 2015
Oral Mucositis - Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Oral Mucositis - Pipeline by ProCertus BioPharm Inc., H1 2015
Oral Mucositis - Pipeline by Soligenix, Inc., H1 2015
Oral Mucositis - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Oral Mucositis - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015

Explore more reports on Cancer Drugs Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs.